| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 160.06 | 1.9% | 0.7% |
| Total Income | 160.26 | 2.0% | 1.6% |
| Expenditure | 145.10 | 3.2% | 6.2% |
| PBT | 15.16 | 11.4% | 85.6% |
| Net Profit | 15.18 | 12.5% | 89.3% |
| OPM | 16.11% | 1.13pp | 20.41pp |
| NPM | 9.47% | 1.22pp | 4.54pp |
| EPS | 4.58 | 11.2% | 87.7% |
Wanbury Ltd Delivers Robust H1 FY26 Performance with 216.6% YoY Jump in PAT
18 Nov 2025 · 18 Nov 2025, 05:41 pm
Summary
Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and half year ended 30 September, 2025. The company reported a robust growth in Profit After Tax (PAT) by 216.6% YoY, driven by volume growth, cost efficiencies, improved Product yield and lower finance cost.
Key Highlights
- 1
Revenue from operations for H1 FY26 stood at Rs. 323.2 crore, up from Rs. 292.3 crore in H1 FY25, reflecting a YoY growth of 10.6%.
- 2
EBITDA (including other income) for H1 FY26 stood at Rs.50.8 crore, compared to Rs. 33.6 crore in H1 FY25, registering a growth of 51.3%.
- 3
PAT for H1 FY26 stood at Rs. 28.7 crore, compared to Rs. 9.1 crore in H1 FY25, registering a growth of 216.6%.
Management Comments
Mr. Mohan Rayana
Director of Wanbury Ltd.
Q2 continues to be stronger with EBITDA achievement of € 26.0 (16.2%) crore as compared to %21.6 (13.3%) crore in Q2 FY25, registering a growth of 20% over previous quarter, overall improvement of 292 bps of revenues. Further, achieved PAT of % 15.2 crore as compared to % 8.0 crore in Q2 FY25, registering a robust growth of approx. 90 % led by cost efficiencies, improved Product yield & lower finance cost.
Informational and educational content only. Not investment advice.